NRX — Nurexone Biologic Income Statement
0.000.00%
- CA$48.52m
- CA$44.09m
- 26
- 12
- 82
- 34
Annual income statement for Nurexone Biologic, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | ARS | ARS | ARS | ARS | ARS |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | fx Final | fx Final | fx Final | Final | Final |
Total Revenue | 0 | 0 | 0 | 0 | 0 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Depreciation and Amortization | |||||
Unusual Expense / Income | |||||
Total Operating Expenses | 0.088 | 0.062 | 0.132 | 7.62 | 3.66 |
Operating Profit | -0.088 | -0.062 | -0.132 | -7.62 | -3.66 |
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -0.065 | -0.021 | -0.132 | -8.17 | -3.64 |
Net Income After Taxes | -0.065 | -0.021 | -0.132 | -8.17 | -3.64 |
Net Income Before Extraordinary Items | |||||
Net Income | -0.065 | -0.021 | -0.132 | -8.17 | -3.64 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -0.065 | -0.021 | -0.132 | -8.17 | -3.64 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -0.026 | -0.008 | -0.052 | -0.161 | -0.081 |